Standards, options and recommendations (SOR) for the management of neutropenic cancer patients (excluding prolonged neutropenia)

被引:0
|
作者
Biron, P
Fuhrmann, C
Escande, MC
Blanc-Vincent, MP
Crokaert, F
Beal, J
Bussy, V
Lesimple, T
Pottecher, B
Raveneau, J
Senet, JM
Viot, M
机构
[1] SOR, FNCLCC, Operat Stand Opt Recommandat, F-75654 Paris 13, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Inst Curie, Paris, France
[4] Inst Jules Bordet, B-1000 Brussels, Belgium
[5] Ctr Oscar Lambret, F-59020 Lille, France
[6] Inst Jean Godinoi, F-51056 Reims, France
[7] Ctr Eugene Marquis, Rennes, France
[8] Ctr Paul Strauss, Strasbourg, France
[9] Ctr Rene Huguenin, St Cloud, France
[10] Ctr Paul Papin, Angers, France
[11] Ctr Antoine Lacassagne, F-06054 Nice, France
关键词
neutropenia; granulocytopenia; guidelines; cancer; neoplasms; infection; chemotherapy; immunocompromised host;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The "Standard, Options and Recommendations" (SOR), initiated in 1993, is a collaborative project between the Federation of the French Cancer Centres (FNCLCC) the 20 French Cancer, Centres and specialists from French Public Universities, General Hospitals and Private Clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and outcomes for cancer patients. The methodology is based on literature review and critical appraisal by a multidisciplinary experts group, with feedback from specialists in cancer care patients. Objective: To develop a clinical practice guideline for the management of neutropenic cancer patients (excluding prolonged neutropenia). Methods: Data have been identified by literature search using Medline and Current Contents (up to February 1997) and personal reference lists. The main end points considered were mortality, morbidity, risk factors fever, source of infection, microbiological documentation, incidence and length of hospital stays, quality of life, efficacy of treatment, safety and costs. Once the guideline was defined, the document was submitted to 48 reviewers for peer review and to the medical committees of the 20 French Cancer Centres for review and agreement Results: The key recommendations are: 1) before receiving cytotoxic chemotherapy, patients most be informed of potential risks and precautions to observe; 2) non-febrile neutropenic patients can be followed at home (except specific context); antibiotic prophylaxis is not recommended 3) initial empirical antibiotic therapy for febrile patients is mandatory, whether associated beta-lactam and aminoglycoside, or monotherapy with a broad-spectrum beta-lactam (except in care of septic shock or pneumopathy). A glycopeptide can be added in care of overt catheter-related or cutaneous infection, in care of microbiologically documented infection with a oxacillin-resistant Cram positive bacteria, or in case of persistent fever in a clinically deteriorating patient; 4) at the present time, there is insufficient evidence to recommend the management of febrile neutropenic patients at home. We recommend participation in studies to identify predicting factors of low-risk patients and to assess the feasibility and safety of early discharge and home therapy.
引用
收藏
页码:695 / 711
页数:17
相关论文
共 50 条
  • [21] Standards, Options and Recommendations (SOR) for clinical care of malignant pleural mesothelioma
    Ruffie, P
    Lehmann, M
    Galateau-Salle, F
    Lagrange, JL
    Pairon, JC
    BULLETIN DU CANCER, 1998, 85 (06) : 545 - 561
  • [22] Standards, options and recommendations for the management of patients with Hodgkin's disease
    Ferme, C
    Cosset, JM
    Fervers, B
    Sebban, C
    Cutuli, B
    Henry-Amar, M
    Stines, J
    Giammarile, F
    Bey, P
    Carella, AM
    Philip, T
    PRESSE MEDICALE, 1999, 28 (40): : 2233 - 2242
  • [23] Standards, options and recommendations for the management of patients with adenocarcinoma of the rectum.
    Blanc-Vincent, MP
    Bécouarn, Y
    Dubois, JB
    Ducreux, M
    Giovannini, M
    Lasser, P
    Rougier, P
    ANNALS OF ONCOLOGY, 2000, 11 : 58 - 58
  • [24] Standards, Options and Recommendations (SOR) for diagnosis, treatment and follow-up of osteosarcoma
    Philip, T
    Blay, JY
    Brunat-Mentigny, M
    Carrie, C
    Chauvot, P
    Farsi, F
    Fervers, B
    Gentet, JC
    Giammarile, F
    Kohler, R
    Mathoulin, S
    Patricot, LM
    Thiesse, P
    BULLETIN DU CANCER, 1999, 86 (02) : 159 - 176
  • [25] Updating 1999 of Standards, Options and Recommendations (SOR) for the clinical use of erythropoietin in oncology
    Spaëth, D
    Marchal, C
    Bataillard, A
    Blanc-Vincent, MP
    BULLETIN DU CANCER, 1999, 86 (7-8) : 631 - 639
  • [27] Standards, Options and Recommendations (SOR) for clinical care of squamous cell carcinoma of the oropharynx
    Renaud-Salis, JL
    Blanc-Vincent, MP
    Brugère, J
    Demard, F
    Faucher, A
    Gory-Delabaere, G
    Pinsolle, J
    BULLETIN DU CANCER, 1999, 86 (06) : 550 - 572
  • [28] Standards, Options and Recommendations for non metastatic breast cancer patients
    Mauriac, L
    Luporsi, E
    Cutuli, B
    Fourquet, A
    Garbay, JR
    Giard, S
    Spyratos, F
    Sigal-Zafrani, B
    Dilhuydy, JM
    Acharian, V
    Balu-Maestro, C
    Blanc-Vincent, MP
    Cohen-Solal, C
    De Lafontan, B
    Dilhuydy, MH
    Duquesne, B
    Gilles, R
    Lesur, A
    Shen, NZ
    BULLETIN DU CANCER, 2002, 89 (02) : 207 - 224
  • [29] Standards, options and recommendations:: Good clinical practice in the dietetic management of cancer patients:: hospital catering
    Dayot, F
    Bataillard, A
    Keré, C
    Ducès, F
    Bachmann, P
    Blanc-Vincent, MP
    Besnard, B
    Bonneteau, C
    Champetier, S
    Claude, M
    Combret, D
    Cometto, F
    Duguet, A
    Duval, N
    Finck, C
    Freby-Lehner, A
    Garabige, V
    Lallemand, Y
    Massoud, C
    Meuric, J
    Montane, C
    Poirée, B
    Puel, S
    Rossignol, G
    Roux-Bournay, P
    Simon, M
    Tran, M
    BULLETIN DU CANCER, 2001, 88 (10) : 1007 - 1018
  • [30] Standards, Options and Recommendations for the management of prostate cancer:: therapeutic decision criteria
    Villers, A
    Du Chatelard, PP
    Pommier, P
    Soulié, M
    Bataillard, A
    Fervers, B
    Bachaud, JM
    Berger, N
    Bertrand, AF
    Bouvier, R
    Brune, D
    Daver, A
    Fontaine, É
    Haillot, O
    Lagrange, JL
    Molinié, V
    Muratet, JP
    Peneau, M
    Prapotnich, D
    Ravery, V
    Richaud, P
    Rossi, D
    BULLETIN DU CANCER, 2002, 89 (06) : 619 - 634